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Purpose: Our previous studies indicated that while 20 nm particles are rapidly cleared from the periocular space of the
rat following posterior subconjunctival injection, 200 nm particles persisted for at least two months. To understand faster
clearance of 20 nm particles, the purpose of this study was to determine transscleral permeability and in vivo disposition
in the presence and absence of circulation. Further, it was the purpose of this study to simulate sustained retinal drug
delivery after periocular administration of rapidly cleared and slowly cleared nanoparticles.
Methods: The permeability of 20 and 200 nm particles over 24 h was examined across isolated bovine sclera and sclera-
choroid-RPE with or without a surfactant (Tween 20, 0.1% w/v) added to the preparation. The in vivo disposition of
nanoparticles was performed using Sprague Dawley rats. The rats, either dead or alive, were administered with 400 µg of
the nanoparticles in the periocular space, and the particle disposition in the eye tissues was assessed 6 h later. To evaluate
the role of the reticulo-endothelial system and lymphatic circulation, isolated liver, spleen, and cervical, axillary, and
mesenteric lymph nodes were analyzed using confocal microscopy. Mathematical simulations with Berkeley Madonna
were used to evaluate the effect of nanoparticle size on retinal drug levels following periocular administration. Celecoxib
was used as the model drug and the finalized pharmacokinetic model from a previous study was used with some
modifications for the simulation.
Results: Transport of 20 nm particles across sclera in the presence and absence of the surfactant were 0.1%±0.07% and
0.46%±0.06%, respectively. These particles did not permeate across the sclera-choroid-RPE in 24 h. There was no
quantifiable transport for 200 nm particles across the sclera or the sclera-choroid-RPE. In live animals, the 20 nm particles
were undetectable in any of the ocular tissues except in the sclera-choroid following periocular administration; however,
in dead animals, the particle concentrations in the sclera-choroid were 19 fold higher than those in live animals, and
particles were detectable in the retina as well as vitreous. The retention of 20 nm particles at the site of administration was
two fold higher in the dead animals. In live animals, the particles were clearly detectable in the spleen and to a very low
extent in the liver as well. The particles were also detected in the cervical, axillary, and mesenteric lymph nodes of the
live animals. Simulations with two particles (20 nm and 200 nm) with different clearance rates demonstrated that the
retinal drug levels were affected by particle clearance. Larger nanoparticles sustained retinal drug delivery better than
smaller nanoparticles. With an increase in drug release rate from the particles, these differences diminish.
Conclusions: The 20 nm particles are transported across the sclera to a minor degree; however, there is no significant
transport across the sclera-choroid-RPE. Periocular circulation (blood and lymphatic) plays an important role in the
clearance of the 20 nm particles. The higher particle levels in the ocular tissues in the post-mortem studies indicate a
dynamic physiologic barrier to the entry of particles into the ocular tissues after periocular administration. The particle
size of the delivery system can play an important role in the observed retinal drug levels after periocular administration.
Slow release nanoparticles with low clearance by blood and lymphatic circulations are suitable for prolonged transscleral
drug delivery to the back of the eye.
The periocular (transscleral) route of delivery is gaining
importance as an alternative to the intravitreal administration
for drug delivery to the choroid, retina, and vitreous [1]. It has
been  demonstrated  that  the  transscleral  route  can  deliver
therapeutically  effective  drug  levels  for  the  treatment  of
choroidal  neovascularization  associated  with  age-related
macular degeneration [2,3]. It has also been demonstrated that
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the periocular (transscleral) route can be used for delivery of
large molecules to the choroid and the retina in vivo [4,5].
Most  of  the  posterior  segment  disorders  like  diabetic
retinopathy and age-related macular degeneration are of a
chronic nature and would require long-term therapy for their
treatment.  Sustained  drug  delivery  systems  can  provide
sustained  drug  levels  to  a  particular  tissue  thereby
significantly reducing the dosing frequency and the associated
complications. Several delivery systems including implants,
scleral plugs, and micro- and nanoparticles have been used for
this purpose [6-10]. Among these systems, the particulate
systems offer several advantages including ease of repeated
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150injections  and  biodegradability.  In  addition,  nanoparticles
have the advantage of cellular entry, which can be used in the
delivery of macromolecules like DNA and proteins inside the
cells [11]. The right combination of the drug/polymer can
control the rate of delivery of a particular drug from these
systems  and  extend  the  duration  for  which  the  drug  is
delivered.
Sustained drug delivery to the retina by the periocular
(transscleral) route would require that the delivery system be
retained at the periocular site for a prolonged time so that the
drug can be released from the device and become available to
the retina. In the case of gene delivery, it would be ideal if the
system penetrates the sclera and enters into the choroid and
retina where the cells in the choroid or the retina can be
transfected. Thus, based on clinical need, the choice of a
particulate delivery system can be made.
We have previously demonstrated that the disposition of
particles after periocular administration is size dependent.
Specifically,  particles  in  the  range  of  200–2000  nm  were
almost completely retained at the site of administration for at
least two months while the smaller 20 nm particles were
cleared  rapidly  from  the  site  of  administration.  We  also
observed that the intra-ocular tissues like the retina and the
vitreous did not have any quantifiable uptake of the particles
of any size [12]. In this study, we investigated the probable
mechanisms for the rapid clearance of 20 nm particles from
the periocular tissue. We also examined the limiting role of
static and dynamic physiologic barriers [13] to the entry of the
nanoparticles  into  the  intra-ocular  tissues  after  periocular
administration.  We  used  in  vitro  permeability  studies  to
determine whether nanoparticles can cross the sclera to gain
access to the choroid and RPE and whether nanoparticles can
cross the choroid-RPE to gain access to the neural retina. To
understand  the  limiting  nature  of  dynamic  physiologic
barriers or circulatory systems, we examined disposition of 20
nm  particles  after  periocular  (posterior  subconjunctival)
administration in live and dead Sprague Dawley (SD) rats.
Microparticles  and  nanoparticles  are  useful  sustained
release drug delivery systems. Based on our investigations,
the particle size of the drug delivery system can not only
influence drug release rates [14] but also particle clearance
[12],  which  means  retinal  drug  delivery.  Thus,  another
objective of this study was to simulate drug levels in the retina
with  administration  of  sustained  drug  delivery  particulate
systems of different particle sizes for a model drug, celecoxib,
for  which  we  recently  developed  a  periocular
pharmacokinetic  model  [15].  In  this  study,  we  simulated
sustained retinal delivery of celecoxib, exhibiting different
periocular clearance rates, following administration of the
drug containing nanoparticles of two different sizes (20 and
200 nm).
METHODS
Materials: Carboxylate modified polystyrene, bodipy-loaded
Fluospheres  (20  nm  and  200  nm)  were  obtained  from
Invitrogen  (Carlsbad,  CA).  Sodium  pentobarbital  was
purchased from Fort Dodge laboratories (Fort Dodge, IA). All
other chemicals were of analytical grade and purchased from
Sigma (St. Louis, MO).
Particle size analysis: Particle size analysis was performed by
dynamic light scattering as previously described [12].
In  vitro  permeability  of  nanoparticles:  The  in  vitro
permeability studies were performed across sclera and the
sclera-choroid-RPE isolated from bovine eye as previously
described [16]. Bovine eyes were obtained from Nebraska
Beef (Omaha, NE). The eyes were kept on ice until dissection.
The total time elapsed between the death of the animals and
the start of the experiment was less than 4 h in this study. The
eye was dissected around the limbus, and the anterior tissues
were removed. The eye was then cut along the geometric axis
then the vitreous and neural retina were separated. For the
sclera-choroid-RPE  combination,  the  tissue  required  no
further processing. To isolate the sclera, the choroid-RPE
layer  was  gently  scraped  off.  The  isolated  tissues  were
mounted in modified Ussing chambers with the scleral surface
facing the donor side and the vitreal surface facing the receiver
side. The bathing fluids were bubbled with 5% CO2, 20%
Figure  1.  Nanoparticle  size  distribution  and  permeability  across
sclera and sclera-choroid-RPE. A: Particle size distribution after 24
h storage in assay buffer used for transport studies. Majority of the
particles are distributed around the 50 nm particle size with another
small group of particles of higher size distribution. B: Particle size
distribution  after  24  h  storage  in  assay  buffer  containing  0.1%
tween-20.  In  the  presence  of  the  surfactant,  the  particle  size
distribution shifts towards greater particle size indicating probable
particle aggregation. C: Transport of nanoparticles (20 nm; 100 µg/
ml) across isolated bovine sclera and sclera-choroid-RPE. The 20 nm
particles  can  cross  the  sclera  but  not  the  sclera-choroid-RPE
combination to any quantifiable extent. D: Transport of nanoparticles
(20 nm; 100 µg/ml) across isolated bovine sclera and sclera-choroid-
RPE in the presence of 0.1% tween-20. The particle transport across
sclera is reduced in the presence of surfactant probably due to the
shift in particle size distribution. Data are expressed as mean ± s.d.
for n = 5-6. No quantifiable transport was observed either across the
sclera or the sclera-choroid-RPE with the 200 nm particles.
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151O2, and 75% N2. The donor chamber contained 1.5 ml of 100
µg/ml solution of Fluospheres (20 nm or 200 nm). At several
time points up to 24 h, 200 µl of the medium was removed
from the receiver chamber and replaced with equivalent assay
buffer. The samples were analyzed using a fluorescence plate
reader (SpectraMax Gemini; Molecular Devices Corporation,
Sunnyvale, CA). To study the effect of surfactant on particle
transport, the same study was performed in the presence of
0.1% Tween 20 (a non-ionic surfactant).
To visualize the transport and diffusion of nanoparticles
through  the  tissue,  confocal  microscopy  was  used.  After
performing the transport across the tissues as described above,
the part of the tissue exposed to the nanoparticle suspension
was cut off from the rest of the tissue and embedded in an
optimal  cutting  temperature  (OCT)  medium  for  frozen
sectioning. The eyes were kept at −80 °C before sectioning.
Sections around 7 µm in thickness were cut and visualized
using a Zeiss confocal laser scanning microscope (Carl-Zeiss
microimaging Inc., Thornwood, NY).
Effect of circulation on the disposition of 20 nm particles:
Carboxylate-modified 20 nm particles (400 µg suspended in
20 µl deionized water) were administered to live or dead
Figure 2. Confocal images of the sclera at the end of the 24 h
nanoparticle  (20  nm)  transport  study.  A  shows  the  control
fluorescence and combined fluorescence while B shows the phase
contrast  images.  C  and  D  are  nanoparticle  exposed  tissue
fluorescence and combined fluorescence and phase contrast images,
respectively. In each image, the scleral (donor) side is on the left and
the  vitreal  (receiver)  side  is  on  the  right.  The  particles  are
concentrated on the outer edge of the sclera. There are very few or
no particles on the vitreal side of the tissue.
Sprague Dawley (SD) rats by periocular administration into
the  posterior  subconjunctival  space  using  a  30G  needle.
Particle uptake in the ocular tissues as well as the retention of
the particles at the periocular site (the tissues in this area
include the subconjunctival fat and muscle as well as the
conjunctiva) was investigated 6 h after the administration.
Since the dead animals were devoid of any circulation and
lymphatic flow unlike live animals, the effect of circulation
and lymphatics on the disposition of the nanoparticles could
be analyzed. All the animal experiments were performed in
compliance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research.
Tissue isolation and quantification of intact particles: Tissue
isolation  and  quantification  of  particles  in  the  ocular  and
periocular tissues were performed as previously described
[12]. Briefly, the ocular tissues, including the sclera-choroid,
retina,  vitreous,  lens,  and  cornea,  were  isolated  from  the
frozen  eye.  The  tissues  were  homogenized  in  1  ml  of
phosphate buffered saline and incubated for 3 h after the
addition of 1 ml of 2% Triton-X solution. The fluorescence
intensity  was  measured  at  the  appropriate  excitation  and
Figure 3. Confocal images of the sclera-choroid-RPE combination
at the end of 24 h nanoparticle (20 nm) transport study. Panel A shows
the  fluorescence  image  and  Panel  B  shows  the  combination
(fluorescence  plus  phase  contrast)  image  of  the  control  sclera-
choroid-RPE tissue. Panel C shows the fluorescence and Panel D
shows the combination (fluorescence plus phase contrast) image of
the  sclera-choroid-RPE  tissue  that  was  exposed  to  nanoparticles
during the transport study. In each panel, the scleral (donor) side is
on the left and the vitreal (receiver) side is on the right. The particles
are concentrated on the outer edge of the sclera. There are very few
or no particles seen on the vitreal side of the tissue.
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152emission wavelengths. The periocular tissues (including the
subconjunctival fat and muscle as well as the conjunctiva)
were homogenized and incubated for 3 h in 1 ml of 2% Triton-
X. The incubation mixture was ultrasonicated at 1.5 W for 3–
5  min,  and  the  tissue  and  supernatant  were  separated  by
centrifugation. The supernatant was diluted appropriately, and
the fluorescence was measured using a Shimadzu RF 5000
spectrofluorometer at the appropriate excitation and emission
wavelengths.
Confocal  microscopy  to  study  the  disposition  of  20  nm
particles: To analyze the mechanism of disposition of the 20
nm particles, the particles were administered to the live SD
rats by periocular injection followed by sacrifice at 6 h. The
eye, the periocular tissue, the liver, and the spleen (organs of
the reticulo-endothelial system or RES) were isolated and
immediately embedded in an OCT medium, and frozen blocks
were prepared. Sections (7 µm) were cut from these blocks
and analyzed by confocal microscopy to detect the presence
of particles in these tissues.
Analysis of nanoparticles in lymph nodes after periocular
injection: SD rats, live and dead, were injected in the posterior
subconjunctival  region  with  400  µg  dose  of  20  nm
nanoparticles in the right eye. Rats, who did not receive an
injection, were treated as controls for tissue autofluorescence.
The rats were euthanized 6 h after nanoparticle administration.
Cervical, axillary, and mesenteric lymph nodes were isolated
and immediately fixed in 4% paraformaldehyde overnight.
Fixed  nodes  were  embedded  in  paraffin  and  sectioned  to
obtain 10 µ-thick sections. Unstained tissue sections were
observed under a confocal microscope at 63x magnification.
Figure 4. Pharmacokinetic modeling of the disposition of 20 nm
particles in the periocular space. Nanoparticle (20 nm) elimination
from the periocular tissue is biphasic. The solid line represents the
model predicted data while the circles represent the observed data.
T1/2α and T1/2β represent half-lives for elimination from the periocular
space. R2: regression coefficient for the correlation between observed
and predicted data.
Statistics: Statistical comparison between the dead and the
live groups were done by using the non- parametric Mann–
Whitney test using SPSS 11.0 (Chicago, IL).
Modeling  the  disposition  of  the  nanoparticles  from  the
periocular  tissue:  The  data  from  this  study  (6  h  in  live
animals) after periocular administration of the 20 nm particles
and a previous study [12] with time points of 1 day, 7, 15, and
60 days were combined to develop a pharmacokinetic model
to describe the disposition of small nanoparticles from the
periocular site of administration. The data were fit to a simple
one-compartment  or  two-compartment  open  model
(intravenous bolus administration) from the existing model
library of WinNonlin 1.5 (Pharsight Corporation, Mountain
View, CA). The best fit model was selected on the basis of
visual data fits and statistical goodness of fit metrics including
the coefficient of determination and the Akaike information
criteria (AIC). All the kinetic parameters were estimated by
WinNonlin.
Simulations  of  retinal  drug  levels  from  sustained  release
particulate systems of celecoxib with different particle sizes:
The finalized model from our previous study, describing the
pharmacokinetics of celecoxib in the retina after periocular
administration [15], was used as the base model in this study.
The previous modeling was based on studies where celecoxib
was administered as a suspension, and the elimination of the
formulation  itself  was  considered  negligible  [15,17,18].
However, if a nanoparticulate sustained drug delivery system
Figure 5. Nanoparticles (20 nm) are cleared by ocular (blood and
lymphatic) circulation. Following periocular administration of 400
µg  dose  of  20  nm  particles  to  either  live  (blood  and  lymphatic
circulation present) or dead rats (blood and lymphatic circulation
absent), the percent dose remaining at the site of administration was
determined 6 h post-dosing. The amount of particles remaining in
the periocular tissue was more than 2 fold higher in the dead rats as
compared to the live rats. The data are expressed as mean ± SEM for
n=4.  The  asterisk  indicates  a  statistically  significant  difference
between live and dead animals (p<0.05).
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153of celecoxib is used for retinal drug delivery after periocular
administration,  the  nanoparticulate  systems  can  have
differential elimination kinetics based on the particle size
[12].  Hence,  we  included  an  elimination  term  for  the
formulation after periocular administration. The half-life for
the removal of 20 nm particles from the periocular space was
assumed to be 5.5 h. The elimination half-life of 200 nm
particles was conservatively assumed to be 180 days (we had
observed almost complete retention of the 200 nm particles
after periocular administration for a period of two months
[12]). Drug levels in the retina were simulated using different
release rates of the drug from the particulate system. All the
other  parameters  for  the  model  were  obtained  from  the
previous study [15]. All simulations were performed using
Berkeley Madonna (Berkeley, CA).
RESULTS
In vitro transport of nanoparticles across isolated bovine
sclera and the sclera-choroid-RPE: The mean hydrodynamic
diameter of the particles measured by dynamic light scattering
was 45 and 230 nm, respectively, for the smaller and larger
Fluospheres. The smaller nanoparticles permeated across the
sclera with the percentage transport at the end of 24 h being
0.46%± 0.064% (Figure 1). No detectable transport was seen
across the sclera-choroid-RPE combination. There was no
detectable transport of the 200 nm particles across either sclera
or sclera-choroid-RPE. Confocal microscopy revealed that
most of the 20 nm particles were concentrated at the edge of
the sclera facing the donor chamber (Figures 2 and 3). A few
Figure  6.  Dynamic  barriers  prevent  significant  entry  of  20  nm
particles into ocular tissues in live animals. Following periocular
administration of 400 µg dose of 20 nm particles to either live (blood
and lymphatic circulation present) or dead rats (blood and lymphatic
circulation  absent)  the  particle  levels  in  the  ocular  tissues  were
quantified. Higher levels of the particles are seen in the sclera-
choroid, retina, vitreous, and the cornea of dead rats as compared to
live rats. The data are expressed as mean ± SEM for n=4.
particles could be seen in the deeper sclera and at the other
Figure 7. Representative confocal micrographs of various tissues 6
h  after  periocular  administration  of  20  nm  particles.  Following
periocular administration of 400 µg dose of 20 nm particles to live
rats, the nanoparticles can be found in the organs of the reticulo-
endothelial system (liver and spleen). The various tissues including
the eye, the periocular tissue, the liver and the spleen were removed
and  sectioned  6  h  after  administration.  The  figure  shows  the
fluorescence  images  of  sections  of  the:  eye  (Panels  A  and  B);
periocular tissue (Panels C and D); liver (Panels E and F); and spleen
(Panels G and H). The left panels (A, C, E, and G) are fluorescence
images from control rats that were not dosed with the nanoparticles
whereas the right panels (B, D, F, and H) are images from the rats
that were dosed with the nanoparticles. Nanoaprticles can be seen in
the periocular tissue, spleen and to some extent in the liver of the
dosed animals.
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154edge.  With  the  surfactant  present,  the  particle  transport
decreased to 0.1%±0.07% (Figure 1C). This decrease was
likely due to the particle aggregation caused by the surfactant
as the measured mean hydrodynamic diameter of particles in
the surfactant preparation was around 253 nm (Figure 1A,B).
Pharmacokinetic  modeling  of  particle  disposition  after
periocular administration: Using the data from the current
and previous study, a model to describe the pharmacokinetics
of  the  periocularly  administered  particles  was  developed
using WinNonlin. The model fits to the data were done using
the one and two-compartmental models (intravenous bolus
models in WinNonlin). Based on visual observations and the
goodness of fit metrics, the two-compartmental model was
selected to describe the kinetics of disposition in the periocular
tissue. The model predicted and the observed data are shown
in Figure 4. The particles showed a biphasic disposition with
half-lives of 5.5 h and 146 h, respectively, for the two phases.
Influence of circulation on the disposition of 20 nm particles:
Circulation played a critical role in the disposition of 20 nm
particles. The retention in the periocular tissue at the end of 6
h of administration in the live animals was 45%±9% whereas
the retention in the dead animals was 77%±3% (Figure 5). The
sclera-choroid tissue levels in the live and dead animals at the
end  of  6  h  were  12±16  ng/mg  and  214±239  ng/mg,
respectively (Figure 6). The particles could not be quantified
in the cornea, retina, and the vitreous of live animals; however,
the particle levels in the cornea, retina, and the vitreous of the
dead animals were 9±8 ng/mg, 13±9 ng/mg, and 22±14 ng/
mg, respectively (Figure 6). In both the live and dead animals,
the particle levels were below quantification limits in the lens.
Distribution  of  20  nm  particles  after  periocular
administration  using  confocal  microscopy:  The  systemic
distribution of 20 nm particles in live rats was analyzed by
confocal microscopy. The particles were seen in the periocular
tissues and to some extent in the spleen. No particles were
detected in the ocular tissues, and only a faint fluorescence
was  found  in  the  liver  6  h  post-administration  of  the
nanoparticles to the rats (Figure 7).
Nanoparticles accumulate in lymph nodes of live rats but not
dead rats: Nanoparticles were detected in all lymph node
sections (cervical, axillary, and mesenteric) of live SD rats
(Figure 8). On the other hand, no fluorescence was observed
when rats were dosed with nanoparticles post-mortem. This
observation suggests that lymphatic drainage might play a
significant  role  in  the  clearance  of  20  nm  polystyrene
nanoparticles from the subconjunctival site of injection.
Simulated  drug  levels  in  the  retina  with  20  and  200  nm
sustained release particles of celecoxib: We simulated the
Figure  8.  Representative  confocal
images of lymph nodes sections 6 h after
periocular  administration  of  20  nm
nanoparticles.  Lymphatic  circulation
plays  a  role  in  the  clearance  of
nanoparticles (20 nm) after periocular
administration. Representative confocal
images of lymph nodes sections, 6 h post
periocular  administration  of  20  nm
nanoparticles.  Nanoparticles  (20  nm;
green)  were  administered  to  SD  rats,
live  (Panels  B,  E,  and  H)  and  dead
(Panels  C,  F,  and  I)  by  periocular
injection.  Lymph  nodes,  namely,
cervical (Panels A-C), axillary (Panels
D-F), and mesenteric (Panels G-I), were
analyzed  for  the  presence  of
nanoparticles by confocal microscopy.
Lymph nodes of undosed SD rats were
treated as controls (Panels  A, D, and
G). Green fluorescence associated with
nanoparticles  was  observed  in  lymph
node sections of live, but not dead, SD
rats 6 h post periocular administration of
nanoparticles. This suggests that in live
animals  lymphatic  drainage  delivered
nanoparticles to various lymph nodes,
however in dead rats, which are devoid
viable lymphatic system, nanoparticles
could not be detected in lymph nodes.
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155retinal drug levels over a 60-day time period in the retina
following periocular administration of celecoxib sustained
release particles (either 20 nm or 200 nm). The simulated
profiles for the particles with different hypothetical first order
release rate constants are shown in Figure 9. It is seen that the
200 nm particles better sustain retinal drug levels at all the
release rates as compared to the 20 nm particles. Also, the
difference between the drug levels with the 20 nm and 200 nm
particles become more apparent when the drug release rates
are lower.
DISCUSSION
In this study, we demonstrate that rapid clearance of 20 nm
particles from the periocular space is due, at least in part, to
the  presence  of  blood  and  lymphatic  circulations  in  the
periocular  region.  Further,  we  demonstrate  that  200  nm
particles do not permeate bovine sclera or sclera-choroid-RPE
over a 24 h period. However, 20 nm particles permeate across
bovine  sclera  but  not  sclera-choroid-RPE.  Further,  our
findings indicate that 200 nm particles do not clear rapidly
from periocular space due to their poor movement across
biological barriers. Due to size-dependent differences in the
clearance  of  nanoparticles  from  the  periocular  space,
differences  in  retinal  delivery  are  to  be  anticipated  for
nanoparticles of different sizes even if the drug release rate is
similar.  Our  simulations  in  this  study  suggest  that  larger
nanoparticles (200 nm) better sustain the retinal drug delivery
compared to smaller particles (20 nm) with the differences
being the highest when the drug release is the slowest.
In  a  previous  study,  we  found  that  there  is  a  size
dependent  disposition  of  nanoparticles  after  periocular
administration  with  the  smaller  particles  (20  nm)  rapidly
cleared from the periocular tissue as compared to the larger
particles (200 nm and 2 µm) [12]. We previously speculated
that  the  rapid  clearance  of  20  nm  particles  was  due  to
periocular blood or lymphatic circulation. In this study, we
provide data to confirm this mechanism. The tissue levels of
the particles in the sclera-choroid, which is the tissue most
adjacent to the site of administration, are 19 fold higher in the
dead animals when compared to the live animals. Since the
periocular retention of the particles in the dead animals is only
two  fold  higher,  concentration  gradient  differences  alone
cannot  explain  the  much  higher  levels  of  the  particles
observed in the sclera-choroid of the dead animals. The higher
Figure 9. Sustained retinal delivery of a
model  drug  (celecoxib)  from
nanoparticles  with  different  clearance
rates and drug release rates. The profiles
were simulated for 20 nm and 200 nm
particles for a period of 60 days. The
elimination  rate  of  the  20  nm
formulation  was  obtained  by  curve
fitting to the previously published data
[12]. The estimated elimination half-life
for  20  nm  particles  was  5.5  h.  The
elimination  half-life  for  the  200  nm
particles was assumed to be 180 days
since they persisted almost completely
for at least two months in the periocular
space [12]. All other model parameters
used in the model are shown in Table 1.
The structural model is shown above the
simulation. The panels depict profiles of
20 and 200 nm particles with a release
rate constant of 0.016 min−1 (A), profiles
of 20 and 200 nm particles with a release
rate  constant  of  0.0016  min−1  (B),
profiles of 20 and 200 nm particles with
a release rate constant of 0.00016 min
−1 (C), and profiles of 20 and 200 nm
particles with a release rate constant of
0.000016 min−1 (D). The insets in each
panel are the profiles for the first 24 h of
drug  release  to  better  show  the  early
differences  between  the  retinal
concentrations  of  celecoxib  using  20
and 200 nm particles.
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156observed levels could be due to the absence of episcleral and/
or choroid circulatory systems in addition to the absence of
other  periocular  clearance  mechanisms.  The  particle
concentrations  are  higher  in  the  retina  and  the  vitreous
(intraocular tissues) of dead animals as compared to the live
animals. In live animals, the levels are below quantification
limits in these tissues at several time points [12]. In addition
to  the  absence  of  periocular  and  choroid  clearance
mechanisms in the dead rats, it is likely that the functional
integrity of the RPE might have declined over time in these
animals as compared to the live animals. Possibly due to a
combination  of  reasons,  including  greater  nanoparticle
retention in the periocular site, greater nanoparticle entry/
retention in the sclera-choroid, and the loss of integrity of RPE
in  the  dead  animals,  we  observed  quantifiable  levels  of
nanoparticles in the retina and vitreous of dead animals but
not in live animals.
Particle levels are also higher in the cornea of the dead
animals as compared to the live animals where the levels are
below quantification limits. Drug transport to the cornea after
periocular administration can partly be due to a leak-back
through the needle track or through the conjunctiva into the
tear  film.  It  has  been  previously  shown  that  there  is  a
significant leak-back of the administered solution/suspension
after periocular administration [19-21]. This leak-back can
contribute to higher drug levels in the cornea at the initial time
points. This has also been demonstrated using compartmental
modeling of corneal pharmacokinetic data by Amrite et al.
[15]. However, such leak-back might be more relevant for a
drug in solution than nanoparticles, especially when there is
no free drug present. A second explanation is that the entry of
nanoparticles  into  the  corneal  epithelium  might  be  less
compared to previously tested drugs for which leak-back was
suggested.  This  is  supported  by  ex-vivo  studies,  which
demonstrate that the corneal epithelium is a significant barrier
to  the  entry  of  particles  into  the  cornea  [22].  A  third
explanation for the lack of quantifiable nanoparticle uptake in
the cornea is that the assay for Fluospheres in tissues is not as
sensitive  as  the  previously  used  assays  for  small  drug
molecules. The higher corneal levels in dead animals at the
end of 6 h could be partly due to the greater periocular space
to  tear  film  concentration  gradient  (two-fold  higher)  and
partly because the elimination processes from the cornea are
shut down. The elimination rate of drugs from the cornea is
high  as  shown  in  several  studies  [23-26]  including  the
modeling studies of Amrite et al. [15].
Using  the  data  from  the  previous  study  [12]  and  an
additional time point of 6 h in this study, we devised a simple
pharmacokinetic model describing the disposition of the 20
nm particles from the periocular tissue. The disposition is
biphasic and can be explained by a two-compartment model.
There is a rapid clearance phase of the particles with a half-
life of 5.5 h followed by a much slower elimination phase with
a half-life of approximately 150 h. The 20 nm particles could
be quantified on day 15 in the periocular tissue but not on day
60 [12] at which point, the levels were considered zero for
half-life estimations.
Bourges et al. [27] demonstrated that large particles can
move  through  the  neural  retina  and  reach  the  RPE  after
intravitreal administration. Bejjani et al. [28] demonstrated
that plasmid-polymer particles administered intravitreally are
able to transfect the retinal pigment epithelium, indicating
their possible movement to these tissues from the vitreous.
However, in the current study, we did not observe significant
permeability  for  200  nm  particles  across  either  sclera  or
sclera-choroid-RPE,  indicating  more  formidable  static
barriers for transscleral nanoparticle delivery. Particles given
intravenously are rapidly cleared from the circulation by the
organs of the reticulo-endothelial system, specifically the liver
and  the  spleen  [29,30].  We  observed  detectable  levels  of
particles  in  the  spleen,  using  confocal  microscopy  after
periocular administration of 20 nm particles. Further, a faint
fluorescence signal was observed in the liver. Thus, particles
enter the blood or lymphatic system from the periocular space
and  eventually  reach  the  organs  of  reticulo-endothelial
system.  Geze  et  al.  [29]  demonstrated  that  following
intravenous administration, the concentration of particles in
the liver was much lower than in the spleen. In addition, we
observed  that  the  particles  accumulated  in  the  cervical,
axillary, and the mesenteric lymph nodes following periocular
administration in live animals. This lymphatic movement of
particles  has  been  demonstrated  previously  for  latex
nanoparticles [31]. It is also known that antigen presented to
the eye can be carried to the lymph nodes as demonstrated in
studies  by  Camelo  et  al.  [32].  Thus,  probably  both  the
circulatory as well as the lymphatic systems play a role in
periocular clearance of the 20 nm particles.
The particles used in this study are non-biodegradable,
commercially  available  Fluospheres  (Invitrogen,  Carlsbad,
CA). The particles are stable for prolonged periods of time in
aqueous media and do not leach out any of the fluorescent
material. Literature from the manufacturer indicates that there
is less than 1% loss of the dye from Fluospheres after six
months of storage in the dark in an aqueous medium and less
than 10% change in the fluorescent signal in xylene after
storage in the dark for six months. The Fluospheres as well as
the dye are inert to alkaline hydrolysis when the temperature
is  maintained  below  60  °C  (Molecular  Probes  product
information; FMRC manual). Thus, it is not very likely that
the  fluorescence  detected  in  intraocular  tissues  is  due  to
leaching of the dye from the Fluospheres.
The particles used in this study are negatively charged
and have a relatively hydrophilic surface. Our previous studies
indicated rapid, substantial clearance of 20 nm, hydrophilic
particles as well as hydrophobic particles from the periocular
site within a day unlike 200 nm and larger particles, which
persisted in the periocular space for at least two months [12].
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157However, the retention of 20 nm, hydrophobic particles in the
periocular space was greater compared to the hydrophilic
ones. However, none of these particles entered the retina to
any significant level. The reason for this, at least in part, is the
poor permeability of nanoparticles across the sclera and more
importantly across the sclera-choroid-RPE as evidenced in
this study. It remains to be seen whether a change in surface
property of nanoparticles including hydrophobicity and an
incorporation  of  a  positive  charge  alters  sclera  or  sclera-
choroid-RPE transport of 20 nm particles.
For sustained drug delivery, the delivery system should
be  retained  at  the  site  of  administration.  If  there  are
mechanisms that lead to the clearance of the delivery system
from  the  site  of  administration,  they  can  have  significant
effects on the observed drug levels in the intended tissue. We
simulated  the  drug  levels  in  the  retina  after  periocular
administration of sustained release nanoparticulate systems of
celecoxib, a model drug. We chose celecoxib because we had
previous  retinal  pharmacokinetic  data  from  periocular
administration  of  celecoxib  to  rats  [17,18].  We  had  also
observed that delivery systems like celecoxib-poly(lactide-
co-glycolide) particles can sustain in vitro release of celecoxib
and deliver therapeutic levels of celecoxib to the retina [33,
34]. In addition, our previous model, developed to describe
the pharmacokinetics of small lipophilic molecules in the
retina after periocular administration, was based on celecoxib
[15]. In the previous model, the elimination of the pure drug
suspension from the periocular tissue was considered to be
negligible,  and  no  elimination  rate  constant  for  the
formulation was included. Based on the earlier study, we fixed
tissue clearance properties for the drug. However, since small
nanoparticles might be cleared more rapidly [12] and because
polymeric particles can slow the drug release rates compared
to  what  can  be  achieved  with  pure  drug  dissolution,  we
incorporated  nanoparticle  clearance  from  the  site  of
administration into the model. We simulated the drug levels
in  the  retina  with  different  release  rates  for  the  delivery
system. We modeled drug release with an initial drug release
rate constant of 0.016 min−1, which is the in vivo dissolution
or release rate constant (Krel) of celecoxib from pure drug
suspension [15]. A sustained delivery system would have
release rates significantly lower than this. Hence, we modeled
releases from 20 nm and 200 nm particles with release rates
over a four-order magnitude range. At all drug release rates,
it is evident that the 200 nm particles best sustained the retinal
drug delivery. The difference in retinal delivery between the
20 and 200 nm particles is larger at slower release rates. The
20 nm particles, due to their more rapid clearance, cannot
sustain retinal drug delivery as well. In Figure 9, we compare
retinal drug levels between 20 and 200 nm particles with same
release rates in each panel. The release of a drug from a matrix
system depends on the surface area of the particles. Hence, on
a purely geometric basis, the release rate from a 200 nm sphere
is expected to be 100 times less than the release rate from a
20 nm sphere of the same composition. Thus, the advantage
of larger particles for sustained retinal drug delivery can be
magnified  when  this  factor  is  taken  into  consideration.
Therefore,  it  is  important  to  consider  the  elimination  of
particles from the site of administration in the design of a
system for sustained drug delivery to the retina.
In  summary,  transscleral  nanoparticle  delivery  is
hindered  by  static  as  well  as  dynamic  barriers.  Larger
nanoparticles  persist  in  the  periocular  space  due  to  their
inability  to  move  across  both  these  barriers.  Smaller
nanoparticles  with  a  diameter  of  about  20  nm,  although
capable of crossing static barriers such as the sclera to some
extent,  are  rapidly  cleared  by  the  blood  and/or  lymphatic
circulations  and  gain  entry  into  organs  of  the  reticulo-
endothelial system such as the spleen and liver. Due to the
rapid clearance of small nanoparticles and because of their
inherent tendency to release the encapsulated drugs at faster
rates, they fail to sustain retinal drug delivery as well as larger
particles. Nanoparticle clearance or delivery system clearance
from the site of administration in addition to the drug release
rate is a critical factor in modeling drug delivery to the target
site.
TABLE 1. MODEL PARAMETERS USED FOR SIMULATIONS OF RETINAL PHARMACOKINETICS AFTER PERIOCULAR ADMINISTRATION OF CELECOXIB IN RATS AS PARTICULATE
FORMULATIONS WITH PARTICLE SIZES, 20 AND 200 NM
Symbol Meaning Value (min−1)
K10 Elimination rate constant from periocular site 0.123
K12 Absorption rate constant for sclera-choroid-RPE (transfer compartment) 3.61E-04
K20 Elimination rate constant from the sclera-choroid-RPE (transfer compartment) 0.035
K23 Absorption rate constant for retina from the sclera-choroid-RPE (transfer compartment) 0.061
K30 Elimination rate constant form the retina 0.002
K34 Rate constant for transfer to the distribution compartment from the retina 0.045
K43 Rate constant for transfer to the retina from the distribution compartment 0.001
Krel Rate constant for the release of the drug from the formulation Different values used
Kelfor Rate constant for elimination of the formulation Value chosen based on the
formulation.
The structural model is shown in Figure 9. Except for the Krel and Kelfor, all other parameters were chosen from a previous
study [15].
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